Top

Published in:

Open Access 01-12-2014 | Research

Higher serum S100B and BDNF levels are correlated with a lower pressure-pain threshold in fibromyalgia

Authors: Simone Azevedo Zanette, Jairo Alberto Dussan-Sarria, Andressa Souza, Alicia Deitos, Iraci Lucena Silva Torres, Wolnei Caumo

Published in: Molecular Pain | Issue 1/2014

Abstract

Background

Fibromyalgia (FM) is conceptualized as a central sensitization (CS) condition, that presents high serum brain-derived neurotrophic factor (BDNF) and neuroglia activation. Although the S100B protein regulates neuroglia functions, it has been traditionally used as a proxy of central nervous system damage. However, neither BDNF nor S100B association with the clinical picture of FM has been elucidated. To explore their association with the pressure-pain threshold (PPT) in FM, we performed a cross-sectional study, including 56 females with confirmed FM aged 18–65 years. Linear regression models were used to adjust for potential confounding factors between serum BDNF, S100B and PPT.

Results

Serum BDNF and S100B were correlated (Spearman’s Rho = 0.29). Serum BDNF (log) and S100B (log) were correlated with the PPT (log) (Partial η² = 0.129, P = 0.012 for the BDNF (log), and Partial η² = 0.105, P = 0.025 for the S100B (log)). Serum BDNF (log) was inversely associated with PPT (log) (β = -1.01, SE = 0.41), age (β = -0.02, SE = 0.15) and obsessive compulsive disorder (β = -0.36, SE = 0.15), while serum S100B (log) was inversely associated with PPT (log) (β = -1.38, SE = 0.50), only.

Conclusions

Both neuroglia key mediators in the CS process were inversely correlated with the PPT. Serum assessment of BDNF and S100B deserve further study to determine its potential as a proxy for the CS spectrum in FM.

Available only for authorised users

Perrot S, Vicaut E, Servant D, Ravaud P: Prevalence of fibromyalgia in France: a multi-step study research combining national screening and clinical confirmation: The DEFI study (Determination of Epidemiology of FIbromyalgia). BMC Musculoskelet Disord 2011, 12: 224.PubMedCentralPubMedCrossRef

Vincent A, Lahr BD, Wolfe F, Clauw DJ, Whipple MO, Oh TH, Barton DL, St Sauver J: Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken) 2013, 65: 786–792.CrossRef

Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010, 62: 600–610.CrossRef

Bennett R: Fibromyalgia: present to future. Curr Rheumatol Rep 2005, 7: 371–376.PubMedCrossRef

Staud R, Rodriguez ME: Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract Rheumatol 2006, 2: 90–98.PubMedCrossRef

Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD: Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001, 91: 165–175.PubMedCrossRef

Woolf CJ: Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011, 152: S2-S15.PubMedCentralPubMedCrossRef

Latremoliere A, Woolf CJ: Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009, 10: 895–926.PubMedCentralPubMedCrossRef

Kawasaki Y, Zhang L, Cheng JK, Ji RR: Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci 2008, 28: 5189–5194.PubMedCentralPubMedCrossRef

10.

Taves S, Berta T, Chen G, Ji RR: Microglia and spinal cord synaptic plasticity in persistent pain. Neural Plast 2013, 2013: 753656.PubMedCentralPubMed

11.

Binder DK, Scharfman HE: Brain-derived neurotrophic factor. Growth Factors 2004, 22: 123–131.PubMedCentralPubMedCrossRef

12.

Asmundson GJ, Norton PJ, Norton GR: Beyond pain: the role of fear and avoidance in chronicity. Clin Psychol Rev 1999, 19: 97–119.PubMedCrossRef

13.

Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ: Transport of brain-derived neurotrophic factor across the blood–brain barrier. Neuropharmacology 1998, 37: 1553–1561.PubMedCrossRef

14.

Poduslo JF, Curran GL: Permeability at the blood–brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res 1996, 36: 280–286.PubMedCrossRef

15.

Rasmussen P, Brassard P, Adser H, Pedersen MV, Leick L, Hart E, Secher NH, Pedersen BK, Pilegaard H: Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp Physiol 2009, 94: 1062–1069.PubMedCrossRef

16.

Ikeda H, Kiritoshi T, Murase K: Contribution of microglia and astrocytes to the central sensitization, inflammatory and neuropathic pain in the juvenile rat. Mol Pain 2012, 8: 43.PubMedCentralPubMedCrossRef

17.

Bianchi R, Giambanco I, Donato R: S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1beta and TNF-alpha. Neurobiol Aging 2010, 31: 665–677.PubMedCrossRef

18.

Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, Geczy CL: Functions of S100 proteins. Curr Mol Med 2013, 13: 24–57.PubMedCentralPubMedCrossRef

19.

Schroeter ML, Abdul-Khaliq H, Sacher J, Steiner J, Blasig IE, Mueller K: Mood disorders are glial disorders: evidence from in vivo studies. Cardiovasc Psychiatry Neurol 2010, 2010: 780645.PubMedCentralPubMedCrossRef

20.

Kleindienst A, Schmidt C, Parsch H, Emtmann I, Xu Y, Buchfelder M: The passage of S100B from brain to blood is not specifically related to the blood–brain barrier integrity. Cardiovasc Psychiatry Neurol 2010, 2010: 801295.PubMedCentralPubMedCrossRef

21.

Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T, Edwards M, Rosmalen CF, Vissers JL: GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 2010, 75: 1786–1793.PubMedCrossRef

22.

Imbe H, Kimura A, Donishi T, Kaneoke Y: Effects of restraint stress on glial activity in the rostral ventromedial medulla. Neuroscience 2013, 241: 10–21.PubMedCrossRef

23.

Luo KR, Hong CJ, Liou YJ, Hou SJ, Huang YH, Tsai SJ: Differential regulation of neurotrophin S100B and BDNF in two rat models of depression. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34: 1433–1439.PubMedCrossRef

24.

Streitburger DP, Arelin K, Kratzsch J, Thiery J, Steiner J, Villringer A, Mueller K, Schroeter ML: Validating serum S100B and neuron-specific enolase as biomarkers for the human brain - a combined serum, gene expression and MRI study. PLoS One 2012, 7: e43284.PubMedCentralPubMedCrossRef

25.

Steiner J, Bernstein HG, Bielau H, Berndt A, Brisch R, Mawrin C, Keilhoff G, Bogerts B: Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 2007, 8: 2.PubMedCentralPubMedCrossRef

26.

Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE: Serum markers support disease-specific glial pathology in major depression. J Affect Disord 2008, 111: 271–280.PubMedCrossRef

27.

Laske C, Stransky E, Eschweiler GW, Klein R, Wittorf A, Leyhe T, Richartz E, Kohler N, Bartels M, Buchkremer G, Schott K: Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J Psychiatr Res 2007, 41: 600–605.PubMedCrossRef

28.

Nugraha B, Korallus C, Gutenbrunner C: Serum level of brain-derived neurotrophic factor in fibromyalgia syndrome correlates with depression but not anxiety. Neurochem Int 2013, 62: 281–286.PubMedCrossRef

29.

Haas L, Portela LV, Bohmer AE, Oses JP, Lara DR: Increased plasma levels of brain derived neurotrophic factor (BDNF) in patients with fibromyalgia. Neurochem Res 2010, 35: 830–834.PubMedCrossRef

30.

Sarchielli P, Mancini ML, Floridi A, Coppola F, Rossi C, Nardi K, Acciarresi M, Pini LA, Calabresi P: Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain 2007, 8: 737–745.PubMedCrossRef

31.

Stefani LC, Torres IL, de Souza IC, Rozisky JR, Fregni F, Caumo W: BDNF as an effect modifier for gender effects on pain thresholds in healthy subjects. Neurosci Lett 2012, 514: 62–66.PubMedCrossRef

32.

Maestu C, Cortes A, Vazquez JM, del Rio D, Gomez-Arguelles JM, del Pozo F, Nevado A: Increased brain responses during subjectively-matched mechanical pain stimulation in fibromyalgia patients as evidenced by MEG. Clin Neurophysiol 2013, 124: 752–760.PubMedCrossRef

33.

Diers M, Yilmaz P, Rance M, Thieme K, Gracely RH, Rolko C, Schley MT, Kiessling U, Wang H, Flor H: Treatment-related changes in brain activation in patients with fibromyalgia syndrome. Exp Brain Res 2012, 218: 619–628.PubMedCrossRef

34.

Harris RE, Sundgren PC, Craig AD, Kirshenbaum E, Sen A, Napadow V, Clauw DJ: Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum 2009, 60: 3146–3152.PubMedCentralPubMedCrossRef

35.

Martinez-Jauand M, Sitges C, Rodriguez V, Picornell A, Ramon M, Buskila D, Montoya P: Pain sensitivity in fibromyalgia is associated with catechol-O-methyltransferase (COMT) gene. Eur J Pain 2013, 17: 16–27.PubMedCrossRef

36.

Fuller-Thomson E, Nimigon-Young J, Brennenstuhl S: Individuals with fibromyalgia and depression: findings from a nationally representative Canadian survey. Rheumatol Int 2012, 32: 853–862.PubMedCrossRef

37.

Giesecke T, Gracely RH, Williams DA, Geisser ME, Petzke FW, Clauw DJ: The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 2005, 52: 1577–1584.PubMedCrossRef

38.

Schatzberg AF: The relationship of chronic pain and depression. J Clin Psychiatry 2004,65(Suppl 12):3–4.

39.

Sairanen M, Lucas G, Ernfors P, Castren M, Castren E: Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci 2005, 25: 1089–1094.PubMedCrossRef

40.

Castro-Sánchez AM, Matarán-Peñarrocha GA, López-Rodríguez MM, Lara-Palomo IC, Arendt-Nielsen L, Fernández-de-las-Peñas C: Gender differences in pain severity, disability, depression, and widespread pressure pain sensitivity in patients with fibromyalgia syndrome without comorbid conditions. Pain Med 2012, 13: 1639–1647.PubMedCrossRef

41.

Wolfe F, Walitt B: Culture, science and the changing nature of fibromyalgia. Nat Rev Rheumatol 2013, 9: 751–755.PubMedCrossRef

42.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Initiative S: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008, 61: 344–349.PubMedCrossRef

43.

Sehn F, Chachamovich E, Vidor LP, Dall-Agnol L, de Souza IC, Torres IL, Fregni F, Caumo W: Cross-cultural adaptation and validation of the Brazilian Portuguese version of the pain catastrophizing scale. Pain Med 2012, 13: 1425–1435.PubMedCrossRef

44.

Bertolazi AN, Fagondes SC, Hoff LS, Dartora EG, Miozzo IC, de Barba ME, Barreto SS: Validation of the Brazilian Portuguese version of the Pittsburgh Sleep Quality Index. Sleep Med 2011, 12: 70–75.PubMedCrossRef

45.

Marques AP, Santos AMB, Assumpção A, Matsutani LA, Lage LV, Pereira CAB: Validação da versão brasileira do Fibromyalgia Impact Questionnaire (FIQ). Rev Bras Reumatol 2006, 46: 24–31.

46.

Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russel IJ, Sheon RP: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33: 160–172.PubMedCrossRef

47.

A-priori Sample Size Calculator for Hierarchical Multiple Regression. http://www.danielsoper.com/statcalc

48.

Katz MH: Multivariable Analysis: A Pratical Guide for Clinicians. New York: Cambridge University Press; 1999.

Title: Higher serum S100B and BDNF levels are correlated with a lower pressure-pain threshold in fibromyalgia
Authors: Simone Azevedo Zanette
Jairo Alberto Dussan-Sarria
Andressa Souza
Alicia Deitos
Iraci Lucena Silva Torres
Wolnei Caumo
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Molecular Pain / Issue 1/2014
Electronic ISSN: 1744-8069
DOI: https://doi.org/10.1186/1744-8069-10-46

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Higher serum S100B and BDNF levels are correlated with a lower pressure-pain threshold in fibromyalgia

Abstract

Background

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

IL-10 mediated by herpes simplex virus vector reduces neuropathic pain induced by HIV gp120 combined with ddC in rats

Role of spinal P2Y6 and P2Y11 receptors in neuropathic pain in rats: possible involvement of glial cells

Loss of long-term depression in the insular cortex after tail amputation in adult mice

Genetic, epigenetic, and mechanistic studies of temporomandibular disorders and overlapping pain conditions

Impaired neuropathic pain and preserved acute pain in rats overexpressing voltage-gated potassium channel subunit Kv1.2 in primary afferent neurons

β-arrestin-2-biased agonism of delta opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) in primary sensory neurons